Navigation Links
CYPHER(R) Sirolimus Drug-Eluting Stent Remains Unsurpassed in Terms of Clinical Safety and Efficacy
Date:9/30/2010

h">
Advanced Search Search

  
Close
  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR New
    '/>"/>

SOURCE Cordis Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. CORDIS Announces Results of Ten-Year CYPHER(R) Sirolimus-Eluting Coronary Stent Follow-Up
2. Positive Long Term Data Presented at ACC 2010 Demonstrate Sustained Safety and Efficacy Advantages of the Cypher(R) Sirolimus Drug-Eluting Stent Over the Endeavor(R) Zotarolimus-Eluting Stent
3. OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) has Lower MACE Rate than TAXUS(R) and CYPHER(R) Stents in Clinical Trial
4. Four Analyses of Three-Year Clinical Data Suggest CYPHER(R) Sirolimus-Eluting Coronary Stent May Provide Alternative to Surgery for Patients with Multivessel Disease
5. Largest Study to Date Shows Significant Reductions in Risks of Blood Clots and Reintervention With CYPHER(R) Sirolimus-eluting Coronary Stent Compared to Taxus Stent
6. Two-Year Outcomes From Large Head-to-Head Clinical Trial Indicate Similar Safety Profile in Diabetic Patients for Cypher(R) Sirolimus-Eluting Coronary Stent and Taxus Stent
7. Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
8. Patient Enrollment Completed in First Randomized Clinical Study of OrbusNeichs Combo™ Bio-engineered Sirolimus Eluting Stent
9. Pre-clinical Data Show OrbusNeichs Combo Bio-engineered Sirolimus Eluting Stent May Offer Advantages to Current Drug Eluting Stent Technologies
10. MacuSight(TM) Announces Positive Preliminary Results From Phase 1 Study of Sirolimus in Wet Age-Related Macular Degeneration
11. MacuSight(TM) Announces Positive Initial Results From Phase 1 Study of Sirolimus in Diabetic Macular Edema
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... 30, 2014   Easy Breathe , the fastest ... announced that it now offers the revolutionary AirSense ... the first sleep apnea therapy devices with internal cellular ... to track and share real-time data on each user,s ... CPAP therapy.  In addition, the internal modem allows the ...
(Date:9/30/2014)... ORANGE , N.J. and NEW BRUNSWICK, N.J., Sept. 30, ... affiliation agreement that allows Kessler Foundation and New ... advance biomedical research, education and patient care programs ... president and chief executive officer of Kessler Foundation ... New Jersey Health Foundation. "The experience ...
(Date:9/30/2014)... , Sept. 30, 2014 The Eastern European ... established medical-device providers as well as new medical-device manufacturers ... while simultaneously looking at ways to reduce the cost ... distributors is one of the effective means to achieve ... distribution market in Eastern European and provides profiles of ...
Breaking Medicine Technology:Easy Breathe Now Offers World's First "Smart" CPAP Device to Treat Sleep Apnea 2Easy Breathe Now Offers World's First "Smart" CPAP Device to Treat Sleep Apnea 3Easy Breathe Now Offers World's First "Smart" CPAP Device to Treat Sleep Apnea 4Kessler Foundation Partners with New Jersey Health Foundation To Start Innovative Companies To Change the Lives of People with Disabilities 2Medical Technologies Distributor Profiles in Eastern Europe 2Medical Technologies Distributor Profiles in Eastern Europe 3
(Date:9/30/2014)... New York, NY (PRWEB) September 30, 2014 ... and falling demand have hampered growth in the ... Popular diets have caused consumers to moderate their ... growing consumer preferences for premium varieties shrunk the ... bread products. Successful operators proactively responded by introducing ...
(Date:9/30/2014)... been awarded a three-year $1.7 million grant from ... new imaging technologies and data analysis techniques that ... of neurons in the brain interact to process ... the precise interactions between millions of nerve cells ... alterations in these interactions that may be responsible ...
(Date:9/30/2014)... September 30, 2014 The American ... to help diabetics curb their sweet tooth, but the ... this September, suggests that zero-calorie sweeteners may actually ... diabetes. , The Weizmann Institute of Science in ... artificial sweeteners to mice, the mice developed glucose intolerance. ...
(Date:9/30/2014)... 2014 Regenerative Medicine Solutions (RMS) is ... in Nashville, Tennessee. RMS welcomes the launch of an ... expansion of a new treatment center for the Lung ... Apnea Institute to Nashville, the hope is to bring ... both diagnosed and undiagnosed. With Nashville being a hub ...
(Date:9/30/2014)... 30, 2014 (HealthDay News) -- Medicare should cover low-dose ... risk for the disease, a coalition of more than ... which includes the Lung Cancer Alliance, the Society of ... Cancer Society and the American Society of Clinical Oncology, ... the U.S. Centers for Medicare & Medicaid Services (CMS). ...
Breaking Medicine News(10 mins):Health News:Bread Production in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Bread Production in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:UMD receives inaugural BRAIN Initiative Award 2Health News:Artificial Sweeteners May be Linked to Greater Diabetes Risk 2Health News:Regenerative Medicine Solutions Expanding 2Health News:Groups Call for Medicare Coverage of Lung Cancer Screening 2
... Small Business Committee Leaders to Press for Affordable ... 24 In advance of tomorrow,s,Finance Committee hearing ... Kerry (D-Mass.) and Olympia J. Snowe (R-Maine), Chairman ... and Entrepreneurship,sent a letter to the leaders of ...
... from a Phase I/II clinical trial of a novel ... In 26 patients with advanced solid tumors, treatment with ... yielding plasma concentrations above the expected therapeutic threshold, says ... in Montreal, Canada. Thallion has produced and tested ...
... seven exceptionally talented and creative investigators in the early ... Health Science (NIEHS), part of the National Institutes of ... made under NIEHSs Outstanding New Environmental Sciences (ONES) program. ... of our efforts to help establish the careers of ...
... supports vitamins for respiratory health , , WEDNESDAY, Oct. 24 (HealthDay ... of drinks a day may help keep the doctor away, ... daily dose of alcohol helps the heart, this study suggests ... for smokers. , "This is the biggest study that,s ever ...
... Oct. 24 Thelen Reid Brown Raysman &,Steiner ... group has,successfully assisted long-time client The Doctors Company ... major provider of healthcare liability,insurance, for an aggregate ... share in cash. (Logo: http://www.newscom.com/cgi-bin/prnh/20071016/AQTU238LOGO ) ...
... trend, PHILADELPHIA, Oct. 24 Governor Edward ... Reduction of Error,Fund (Mcare) claims have dropped by ... result of reforms, more insurers are writing malpractice ... when it comes to medical malpractice,",Governor Rendell said ...
Cached Medicine News:Health News:Kerry, Snowe Push Finance Committee on Small Business Health Care 2Health News:Kerry, Snowe Push Finance Committee on Small Business Health Care 3Health News:Phase I pharmacokinetic study of ECO-4601, a novel bifunctional targeting agent 2Health News:NIEHS awards outstanding new environmental scientists 2Health News:Drink or Two a Day May Help Lungs 2Health News:Drink or Two a Day May Help Lungs 3Health News:Drink or Two a Day May Help Lungs 4Health News:Thelen Assists The Doctors Company in Acquisition of SCPIE Holdings Inc. 2Health News:Governor Rendell Says Mcare Claims and Costs Are 50 Percent Lower Than in 2003 2
The CK method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of creatine kinase activity in serum and plasma...
For the quantitative in vitro determination of Cholesterol in serum and plasma....
For the quantitative in vitro determination of Alanine Aminotransferase (ALT) in serum and plasma....
... introduces the Tag-It™ Cystic Fibrosis Kit, the ... genotyping. With validated performance criteria, this highly ... superior mutation coverage for carrier screening in ... in newborns. ,The Tag-It™ Cystic Fibrosis ...
Medicine Products: